Abstract
Age-related macular degeneration is gradually becoming a priority of ophthalmology due to population development. At least 25% of patients over the age of 60 have some degree of disability.
The possibilities of diagnosis, therapy and treatment options and regimens are constantly expanding, so the publications published on this topic in the Czech Republic no longer contain up-to-date information. In addition to generally known facts, in the book Age-related macular degeneration, we learn about the possibilities of dry form therapy, gene therapy and stem cell treatment.
There is also a chapter on novelties in the field of anti-VEGF pharmacotherapy and biosimilar drugs.